NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11
08/04/2022 - 06:50 AM
EMERYVILLE, Calif. --(BUSINESS WIRE)--
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2022 after market close on Thursday, August 11, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time .
Date/Time :
Thursday, August 11 , 4:30 p.m. ET / 1:30 p.m. PT
Pre-Registration:
Participants can pre-register for the conference call here :
Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Dial In:
Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:
866-777-2509 from within the U.S.
412-317-5413 from outside the U.S.
The live webcast of the conference call also will be available at http://novabay.com/investors/events . A replay of the call will be available beginning two hours after its completion through September 1, 2022 by dialing 877-344-7529 from within the U.S. , 855-669-9658 from Canada or 412-317-0088 from outside the U.S. , and entering conference ID 9678917. The webcast will also be archived at http://novabay.com/investors/events .
About NovaBay Pharmaceuticals, Inc :
NovaBay Pharmaceuticals, Inc. creates science-based, problem-solving, accessible solutions for improved well-being through its two brands, Avenova® and DERMAdoctor® . Avenova products are scientifically created and clinically proven to help patients and consumers with common eye irritations. DERMAdoctor products are premium dermatologist-developed skincare solutions sold through traditional domestic retailers, digital beauty channels and international distributors.
Socialize and Stay Informed on NovaBay ’ s Progress
Facebook
Twitter
LinkedIn
Website
Avenova Purchasing Information
sales@avenova.com
Avenova.com
DERMAdoctor Purchasing Information
service@dermadoctor.com
DERMAdoctor.com
View source version on businesswire.com : https://www.businesswire.com/news/home/20220804005129/en/
NovaBay Contact
Justin Hall
jhall@novabay.com
Investor Contact
Jody Cain
jcain@lhai.com
Source: NovaBay Pharmaceuticals, Inc.
Novabay Pharmaceuticals Inc
NBY Rankings
N/A Ranked by Stock Gains
NBY Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Emeryville
About NBY
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
